{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:00:28Z","timestamp":1760608828955},"reference-count":38,"publisher":"Microbiology Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,12,1]]},"abstract":"<jats:p>Replicon-particle-based vaccines combine the efficacy of live-attenuated vaccines with the safety of inactivated or subunit vaccines. Recently, we developed Rift Valley fever virus (RVFV) replicon particles, also known as nonspreading RVFV (NSR), and demonstrated that a single vaccination with these particles can confer sterile immunity in target animals. NSR particles can be produced by transfection of replicon cells, which stably maintain replicating RVFV S and L genome segments, with an expression plasmid encoding the RVFV glycoproteins, Gn and Gc, normally encoded by the M-genome segment. Here, we explored the possibility to produce NSR with the use of a helper virus. We show that replicon cells infected with a Newcastle disease virus expressing Gn and Gc (NDV-GnGc) were able to produce high levels of NSR particles. In addition, using reverse genetics and site-directed mutagenesis, we were able to create an NDV-GnGc variant that lacks the NDV fusion protein and contains two amino acid substitutions in, respectively, Gn and HN. The resulting virus uses a unique entry pathway that facilitates the efficient production of NSR in a one-component system. The novel system provides a promising alternative for transfection-based NSR production.<\/jats:p>","DOI":"10.1099\/vir.0.067660-0","type":"journal-article","created":{"date-parts":[[2014,9,11]],"date-time":"2014-09-11T07:08:20Z","timestamp":1410419300000},"page":"2638-2648","source":"Crossref","is-referenced-by-count":4,"title":["Paramyxovirus-based production of Rift Valley fever virus replicon particles"],"prefix":"10.1099","volume":"95","author":[{"given":"Paul J.","family":"Wichgers Schreur","sequence":"first","affiliation":[{"name":"Department of Virology, Central Veterinary Institute of Wageningen University and Research Centre, Lelystad, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Oreshkova","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Immunology, Virology Division, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands"},{"name":"Department of Virology, Central Veterinary Institute of Wageningen University and Research Centre, Lelystad, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Harders","sequence":"additional","affiliation":[{"name":"Department of Infection Biology, Central Veterinary Institute of Wageningen University and Research Centre, Lelystad, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Bossers","sequence":"additional","affiliation":[{"name":"Department of Infection Biology, Central Veterinary Institute of Wageningen University and Research Centre, Lelystad, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob J. M.","family":"Moormann","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Immunology, Virology Division, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands"},{"name":"Department of Virology, Central Veterinary Institute of Wageningen University and Research Centre, Lelystad, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen","family":"Kortekaas","sequence":"additional","affiliation":[{"name":"Department of Virology, Central Veterinary Institute of Wageningen University and Research Centre, Lelystad, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"345","reference":[{"key":"r1","first-page":"155","article-title":"Rift Valley fever vaccine\u2013antibody and immune response in cattle to a live and an inactivated vaccine","volume":"50","author":"Barnard","year":"1979","journal-title":"J S Afr Vet Assoc"},{"key":"r2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.18.9798-9806.2004"},{"key":"r3","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.3.1371-1377.2001"},{"key":"r4","doi-asserted-by":"publisher","DOI":"10.3390\/v4040613"},{"key":"r5","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.82940-0"},{"key":"r6","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.12.062"},{"key":"r7","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01973-12"},{"key":"r38","doi-asserted-by":"crossref","first-page":"13767","DOI":"10.1128\/JVI.01364-12","article-title":"Heparan Sulfate Facilitates Rift Valley Fever Virus Entry into the Cell","volume":"86","author":"de Boer","year":"2012b","journal-title":"J Virol"},{"key":"r8","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.80822-0"},{"key":"r9","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.07104-11"},{"key":"r10","doi-asserted-by":"publisher","DOI":"10.1186\/1297-9716-42-122"},{"key":"r11","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-71-3-501"},{"key":"r12","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/BF03401814","article-title":"Emerging viruses: the Bunyaviridae","volume":"3","author":"Elliott","year":"1997","journal-title":"Mol Med"},{"key":"r13","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.027540-0"},{"key":"r14","doi-asserted-by":"publisher","DOI":"10.2307\/1589696"},{"key":"r15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000287"},{"key":"r16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.05054.x"},{"key":"r17","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/JVI.62.3.826-833.1988","article-title":"Rift Valley fever virus M segment: use of recombinant vaccinia viruses to study Phlebovirus gene expression","volume":"62","author":"Kakach","year":"1988","journal-title":"J Virol"},{"key":"r18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1128\/JVI.58.2.263-270.1986","article-title":"Use of bacterial expression cloning to define the amino acid sequences of antigenic determinants on the G2 glycoprotein of Rift Valley fever virus","volume":"58","author":"Keegan","year":"1986","journal-title":"J Virol"},{"key":"r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.04.048"},{"key":"r20","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00841-11"},{"key":"r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.03.027"},{"key":"r22","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.1923"},{"key":"r23","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02399-10"},{"key":"r24","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.24.12622-12633.2002"},{"key":"r25","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbs012"},{"key":"r26","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4269\/ajtmh.1995.53.405","article-title":"Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment","volume":"53","author":"Muller","year":"1995","journal-title":"Am J Trop Med Hyg"},{"key":"r27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077461"},{"key":"r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.07.051"},{"key":"r29","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1128\/JVI.73.6.5001-5009.1999","article-title":"Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence","volume":"73","author":"Peeters","year":"1999","journal-title":"J Virol"},{"key":"r30","doi-asserted-by":"publisher","DOI":"10.1007\/s007050070059"},{"key":"r31","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01965-12"},{"key":"r32","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1099\/0022-1317-80-11-2987","article-title":"Generation of recombinant lentogenic Newcastle disease virus from cDNA","volume":"80","author":"R\u00f6mer-Oberd\u00f6rfer","year":"1999","journal-title":"J Gen Virol"},{"key":"r33","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.11.5101-5107.2000"},{"key":"r34","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02192-12"},{"key":"r35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087385"},{"key":"r36","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01238-07"},{"key":"r37","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.938"}],"container-title":["Journal of General Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jgv\/10.1099\/vir.0.067660-0?crawler=true","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T01:32:16Z","timestamp":1603762336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jgv\/10.1099\/vir.0.067660-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,1]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12,1]]}},"URL":"https:\/\/doi.org\/10.1099\/vir.0.067660-0","relation":{},"ISSN":["0022-1317","1465-2099"],"issn-type":[{"value":"0022-1317","type":"print"},{"value":"1465-2099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,1]]}}}